Detail akcie Apogee Therap Rg online

Business Summary: Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4R?. APG279 is for the dual inhibition of OX40L and IL-13.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Apogee Therapeutics Inc revenues was not reported. Net loss increased 62% to $186.5M. Higher net loss reflects United States segment loss increase of 33% to $136.3M. Basic Earnings per Share excluding Extraordinary Items decreased from -$2.03 to -$3.19.